Results 91 to 100 of about 178 (122)

Abstract 3538: Endogenous HiBiT-tagging of PAX3-FOXO1 identifies potent suppressors of PAX3-FOXO1 protein levels by high-throughput screening

Cancer Research, 2023
Abstract Background: Oncogenic fusion genes are attractive therapeutic targets due to their tumor-specific expression and driver roles in cancers. PAX3-FOXO1 (P3F) is the dominant oncogenic driver of fusion-positive rhabdomyosarcoma (FP-RMS) with no targeted therapy.
Yong Yean Kim, Robert G. Hawley, Mehal Churiwal, Teresa S. Hawley, Christine N. Evans, Raj Chari, David Milewski, Ranuka Sinniah, Young K. Song, Hsien-Chao Chou, Xinyu Wen, Ying Pang, Jing Wu, Craig J. Thomas, Jun S. Wei, Michele Ceribelli, Javed Khan   +16 more
openaire   +1 more source

PAX3‐FOXO1 and FGFR4 in alveolar rhabdomyosarcoma

Molecular Carcinogenesis, 2011
AbstractWe and others have identified FGFR4 as a direct transcriptional target of the alveolar rhabdomyosarcoma (ARMS) specific fusion protein, PAX3‐FOXO1. We hypothesized fibroblast growth factor receptor 4 (FGFR4) may act as an effector of PAX3‐FOXO1, contributing to PAX3‐FOXO1 tumorigenic phenotypes.
Amy D, Marshall, Martijn A, van der Ent, Gerard C, Grosveld   +2 more
openaire   +2 more sources

Myo-differentiation reporter screen reveals NF-Y as an activator of PAX3–FOXO1 in rhabdomyosarcoma

Proceedings of the National Academy of Sciences of the United States of America, 2023
Recurrent chromosomal rearrangements found in rhabdomyosarcoma (RMS) produce the PAX3–FOXO1 fusion protein, which is an oncogenic driver and a dependency in this disease. One important function of PAX3–FOXO1 is to arrest myogenic differentiation, which is linked to the ability of RMS cells to gain an unlimited proliferation ...
MARTYNA Sroka, Gerd Blobel, Christopher Vakoc   +2 more
exaly   +3 more sources

Transcriptional complexes involving PAX3‐FOXO1

The FASEB Journal, 2016
Rhabdomyosarcoma is a rare soft tissue cancer that most often affects children and young adults but can occur at any age. Of the three types of Rhabdomyosarcoma, Embryonal, Alveolar, and Anaplastic, we focus on Alveolar Rhabdomyosarcoma (ARMS).
Amber Weatherspoon, Tess Cherlin, Kelly Johanson   +2 more
openaire   +1 more source

Is PAX3-FOXO1 associated with worse outcome in adults with rhabdomyosarcoma (RMS)?

Journal of Clinical Oncology, 2019
e22525 Background: Rhabdomyosarcoma (RMS) is a rare soft tissue sarcoma in adults. The PAX3-FOXO1 fusion gene is associated with alveolar rhabdomyosarcoma. PAX3-FOXO1 results from a stable reciprocal translocation of chromosomes 2 and 13, which fuses in-frame the DNA binding domain of PAX3 with the transactivation domain of FOXO1.
Sheena Guram, Julia Dirks, Shivali Barot, Anthony Griffin, Ilan Weinreb, Elizabeth Demicco, David Benjamin Shultz, Albiruni Ryan Abdul Razak, Rebecca Anne Gladdy, Abha A. Gupta   +9 more
openaire   +1 more source

Anlotinib destabilizes PAX3-FOXO1 to induce rhabdomyosarcoma cell death via upregulating NEK2

Biomedicine and Pharmacotherapy
Rhabdomyosarcoma (RMS) is one of the most common soft tissue sarcomas in children and adolescents, in which PAX3-FOXO1 fusion gene positive patients have very poor prognosis. PAX3-FOXO1 has been identified as an independent prognostic predictor in RMS, with no currently available targeted therapeutic intervention.
Tongyuan Qu, Yankun Chen
exaly   +3 more sources

Investigating the Role of a Dual Motif in DNA Binding by PAX3‐FOXO1

The FASEB Journal, 2017
Rhabdomyosarcoma (RMS) is a common soft tissue sarcoma that can be divided into two main categories. Embryonal Rhabdomyosarcoma (ERMS) usually affects children in the first five years of life and has not been linked to the presence of specific gene fusions.
Amber Weatherspoon, Ronise Evans, Tess Cherlin, Melyssa Bratton, Kelly Johanson   +4 more
openaire   +1 more source

Abstract PR16: Targeting the chromatin architecture established by PAX3-FOXO1 in rhabdomyosarcoma

Cancer Research, 2016
Abstract Master transcription factors establish enhancers to regulate cell identity genes by recruiting epigenetic machinery, and are sequentially exchanged during changes in cell identity (ie, differentiation). Commonly, the fusion of transcription factors profoundly alters proper progression of cell identity, serving as the signature ...
Berkley E. Gryder, Marielle E. Yohe, Jack Shern, Hsien-Chao Chou, Young Song, Rajesh Patidar, Sam Li, Sivasish Sindiri, Abigail Cleveland, Hongling Liao, Xinyu Wen, Xiaohu Zhang, Lesley Mathews-Griner, Rajarshi Guha, Paul Shinn, Marc Ferrer, Scott Martin, Madhu Lal, Craig Thomas, Javed Khan   +19 more
openaire   +1 more source

Abstract A001: PAX3-FOXO1-induced transcriptional dysregulation in rhabdomyosarcoma

Cancer Research
Abstract The survival rate for high-risk rhabdomyosarcoma (RMS) has not increased above 20% in the last thirty years. This insufficiency persists despite thorough molecular characterization of existing models and patient tumors, which has demonstrated that the most challenging RMS tumors harbor chromosomal translocations generating PAX3 ...
Bradley T. Stevens, Yang Zhang, Randolph K. Larsen, Grace E. Adkins, Jack D. Hopkins, Darden W. Kimbrough, Matthew R. Garcia, Mark E. Hatley, Brian J. Abraham   +8 more
openaire   +1 more source

Investigation of PAX3‐FOXO1 Effect on NEAT1 Expression in Alveolar Rhabdomyosarcoma Cells

The FASEB Journal, 2017
Rhabdomyosarcoma (RMS) is pediatric sarcoma in the soft muscular tissue. One of the two major types of rhabdomyosarcoma is alveolar rhabdomyosarcoma (ARMS). ARMS generally occurs in muscles in the abdomen, arms, and legs. Due to its tendency to grow more rapidly, it is a more aggressive form of the cancer that has a higher risk factor than other forms ...
Victoria Agbeke George, Brianyell McDaniel, Kelly E. Johanson   +2 more
openaire   +1 more source